IMU is more likely to end up with 100b shares on issue than market valuation given the current cash burn rate.
don’t get me wrong, I wish IMU every success. Will be good for the local biotech sector if the company shoots the lights out, with cashed up, risk averse biotech shareholders!
Just not overly impressed by IMUs therapy pipeline and management on a relative and absolute basis. Happy to be corrected on any of my comments.
Add to My Watchlist
What is My Watchlist?
